Logo image
Pyrroloquinoline quinone influences intracellular alpha-synuclein aggregates
Journal article   Open access   Peer reviewed

Pyrroloquinoline quinone influences intracellular alpha-synuclein aggregates

Elizabeth Mountford, Cynthia Mathew, Reena Ghildyal and Andrea Bugarcic
Experimental Results, Vol.4, pp.1-13
2023
pdf
Pyrroloquinoline Quinone (PQQ) Influences Intracellular Alpha-Synuclein Aggregates981.13 kBDownloadView
AcceptedCC BY-NC-ND V4.0 Open Access
url
Pyrroloquinoline Quinone (PQQ) Influences Intracellular Alpha-Synuclein AggregatesView
AcceptedCC BY-NC-ND V4.0 Open

Related links

Metrics

157 File views/ downloads
61 Record Views

Abstract

alpha-synuclein a-synuclein aggregation Lewy Body nutrition nutritional supplements Parkinson's disease Pyrroloquinoline quinone PQQ
Parkinson's disease (PD) is an irreversible neurodegenerative disorder clinically manifesting in uncontrolled motor symptoms. There are two primary hallmark features of Parkinson's disease - an irreversible loss of dopaminergic neurons of the substantia nigra pars compacta and formation of intracellular insoluble aggregates called Lewy bodies mostly composed of alpha-synuclein. Using a clinical improvements-first approach, we identified several clinical trials involving consumption of a specific diet or nutritional supplementation improved motor and non-motor functions. Here, we aimed to investigate if and how pyrroloquinoline quinone (PQQ) compound disrupts pre-formed alpha28 synuclein deposits using SH-SY5Y cells, widely used Parkinson’s Disease cellular model. SH-SY5Y neuroblastoma cells, incubated in presence of potassium chloride (KCl) to induce alpha30 synuclein protein aggregation, were treated with PQQ for up to 48 hours. Resulting aggregates were examined and quantified using confocal microscopy. Overall, nutritional compound PQQ reduced the average number and overall size of intracellular cytoplasmic alpha-synuclein aggregates in a PD cellular model.

Details

Logo image